diabetic%20ketoacidosis%20-and-%20hyperosmolar%20hyperglycemic%20state
DIABETIC KETOACIDOSIS & HYPEROSMOLAR HYPERGLYCEMIC STATE
Diabetic ketoacidosis is characterized by having blood glucose >13.9 mmol/L, arterial pH <7.3 in adults or venous pH <7.3 in pediatrics, bicarbonate <15 mEg/L, moderate ketonuria or ketonemia and anion gap >14.
Hyperosmolar hyperglycemic state in adults is described as having blood glucose >33.3 mmol/L, arterial pH >7.3, bicarbonate >15 mEq/L, mild ketonuria or ketonemia, effective serum osmolality >320 mOsm/kg and variable anion gap.
Hyperosmolar hyperglycemic state in pediatric patients has blood glucose >33.3 mmol/L, venous pH >7.3, bicarbonate >15 mEq/L and altered mental status or severe dehydration.

Diabetic%20ketoacidosis%20-and-%20hyperosmolar%20hyperglycemic%20state Treatment

Pharmacotherapy

  • DKA & HHS patients are best managed in the intensive care unit w/ the care of a specialist/endocrinologist

Intravenous (IV) Fluids

  • Initial therapy aims to restore renal perfusion, & expand intravascular & extravascular volume
  • Fluid deficits should be corrected w/in the first 24 hours of treatment
  • Serum Na should be corrected for hyperglycemia (for each 5.6 mmol/L glucose >5.6 mmol/L, add 1.6 mmol to Na value for corrected serum Na value)
  • Serum osmolality change should not be >3 mOsm/kg H2O/hour
  • Avoid iatrogenic fluid overload by frequently monitoring cardiac, renal & mental status
  • In pediatric patients, initial fluid expansion should not be >50 mL/kg over first 4 hours of treatment
    • Fluid deficits should be corrected over 48 hours of treatment

Insulin

  • Ketonemia usually takes longer to clear than hyperglycemia
  • May or may not be aggressive w/ insulin administration depending on patient hydration
  • If patient presents w/ severe hypokalemia, insulin treatment should be delayed until K serum concentration is restored to >3.3 mmol/L to avoid respiratory arrest & arrhythmias
  • There should be an overlap of IV insulin & subcutaneous (SC) insulin of 1-2 hours to ensure adequate glucose control
    • An abrupt discontinuation of IV insulin w/ a delayed onset of SC insulin may result in inadequate glucose control
  • In newly diagnosed diabetics the initial total insulin dose should be ~0.5-1 U/kg/day given in ≥2 divided doses
    • Include both short-acting & long-acting insulin
    • Continue until optimal dosing is established

Potassium

  • Correction of acidosis, volume expansion & insulin therapy decrease serum K concentration
    • Hypokalemia may be avoided by K replacement 

Bicarbonate

  • Studies have failed to show benefit or deleterious changes in morbidity or mortality w/ bicarbonate use in diabetic ketoacidosis (DKA) patients w/ pH between 6.9-7.1
  • Insulin & bicarbonate can lower serum K & supplementation may be required

Phosphate

  • Patients w/ cardiac dysfunction, anemia or respiratory depression may benefit from careful phosphate replacement
    • Hypophosphatemia may cause cardiac & skeletal muscle weakness, & respiratory depression

Somatostatin

  • Though not considered standard therapy, Somatostatin may be added if patients are resistant to conventional DKA therapy
  • Effects: Decrease glucagon secretion & inhibit ketogenesis
Editor's Recommendations
Most Read Articles
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Roshini Claire Anthony, 2 days ago

Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.

Roshini Claire Anthony, 08 Jun 2021

Year 6 and 7 cumulative data from the Mirena Extension Trial suggest that the efficacy and safety of the levonorgestrel-releasing intrauterine system (LNG-IUS) as a contraceptive method is maintained over this time frame.

06 May 2021
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.